🚀 VC round data is live in beta, check it out!
Kalaris Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kalaris Therapeutics and similar public comparables like Humacyte, Alpha Cognition, Biomea Fusion, Journey Medical and more.
Kalaris Therapeutics Overview
About Kalaris Therapeutics
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Founded
2019
HQ
Employees
6
Website
Sectors
Financials (LTM)
EV
$21M
Kalaris Therapeutics Financials
Kalaris Therapeutics reported last 12-month revenue of —.
In the same LTM period, Kalaris Therapeutics generated — in gross profit and had net loss of ($45M).
Revenue (LTM)
Kalaris Therapeutics P&L
In the most recent fiscal year, Kalaris Therapeutics reported revenue of — and EBITDA of ($42M).
Kalaris Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($42M) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($43M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kalaris Therapeutics Stock Performance
Kalaris Therapeutics has current market cap of $138M, and enterprise value of $21M.
Market Cap Evolution
Kalaris Therapeutics' stock price is $6.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21M | $138M | -6.0% | XXX | XXX | XXX | $-1.89 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKalaris Therapeutics Valuation Multiples
Kalaris Therapeutics trades at (0.5x) EV/EBITDA.
Kalaris Therapeutics Financial Valuation Multiples
As of April 10, 2026, Kalaris Therapeutics has market cap of $138M and EV of $21M.
Equity research analysts estimate Kalaris Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kalaris Therapeutics has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.4x) | XXX | (0.5x) | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kalaris Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kalaris Therapeutics Margins & Growth Rates
Kalaris Therapeutics' revenue in the last fiscal year grew by —.
Kalaris Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $7.7M for the same period.
Kalaris Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (37%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $7.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kalaris Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Humacyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomea Fusion | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Guerbet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kalaris Therapeutics M&A Activity
Kalaris Therapeutics acquired XXX companies to date.
Last acquisition by Kalaris Therapeutics was on XXXXXXXX, XXXXX. Kalaris Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kalaris Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKalaris Therapeutics Investment Activity
Kalaris Therapeutics invested in XXX companies to date.
Kalaris Therapeutics made its latest investment on XXXXXXXX, XXXXX. Kalaris Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kalaris Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kalaris Therapeutics
| When was Kalaris Therapeutics founded? | Kalaris Therapeutics was founded in 2019. |
| Where is Kalaris Therapeutics headquartered? | Kalaris Therapeutics is headquartered in United States. |
| How many employees does Kalaris Therapeutics have? | As of today, Kalaris Therapeutics has over 6 employees. |
| Who is the CEO of Kalaris Therapeutics? | Kalaris Therapeutics' CEO is Andrew Oxtoby. |
| Is Kalaris Therapeutics publicly listed? | Yes, Kalaris Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Kalaris Therapeutics? | Kalaris Therapeutics trades under KLRS ticker. |
| When did Kalaris Therapeutics go public? | Kalaris Therapeutics went public in 2025. |
| Who are competitors of Kalaris Therapeutics? | Kalaris Therapeutics main competitors are Humacyte, Alpha Cognition, Biomea Fusion, Journey Medical. |
| What is the current market cap of Kalaris Therapeutics? | Kalaris Therapeutics' current market cap is $138M. |
| Is Kalaris Therapeutics profitable? | No, Kalaris Therapeutics is not profitable. |
| What is the current net income of Kalaris Therapeutics? | Kalaris Therapeutics' last 12 months net income is ($45M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.